Epidiolex is the first plant-based drug derived from cannabis and approved for treatment in the US. See what the research says about taking CBD oil for epilepsy now.
What does the research say about cannabis and epilepsy?
Epilepsy is a neurological disorder in which nerve cell activity in the brain becomes disrupted and causes seizures or periods of unusual behavior, sensations, and sometimes loss of consciousness.
Roughly 30% of patients with epilepsy have a treatment-resistant form that makes their symptoms worse and increases their risk of death.
On June 25, 2018, the US Food & Drug Administration (FDA) approved a drug called Epidiolex® to treat two rare, severe forms of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome, in patients over the age of two.
Epidiolex is an oral solution made of cannabidiol, making it the first plant-based drug derived from cannabis and approved by the FDA in the US . It’s also the first FDA approved medication to treat seizures in those with Dravet syndrome.
This is a milestone in establishing cannabidiol, or CBD, as a safe and effective treatment for epilepsy.
But what is CBD and what does the research on cannabis and epilepsy show?
The cannabis plant contains hundreds of compounds called cannabinoids. These cannabinoids act on cannabinoid receptors in the body to produce different therapeutic effects.
The two most studied and discussed cannabinoids are:
Tetrahydrocannabinol, or THC, which causes the psychoactive “high” and mental impairment when using marijuana.
Cannabidiol, or CBD, which does not have any psychoactive properties and has been studied for its many positive health benefits.
One of the newly researched health benefits of CBD is seizure reduction.
Though CBD has shown anticonvulsant properties in many animal studies, there’s been limited data in human trials due to marijuana still being illegal on the federal level .
With wider marijuana legalization across the country, scientists are learning CBD may provide neuroprotective and anti-inflammatory benefits as well .
While the reasons CBD works against seizures isn’t fully understood yet, evidence from clinical trials suggests it may be effective for treatment-resistant epilepsy.
Epidiolex is a purified CBD extract (>99% CBD) with a known and consistent amount of CBD in each dose.
Researchers in controlled clinical trials of Epidiolex gave participants CBD oil or a placebo in addition to their pre-existing epilepsy medication.
In one study, a total of 225 people were enrolled in three groups taking either:
20mg of CBD oil
10mg of CBD oil
No CBD oil
After 14 weeks of twice daily CBD administration, drop seizures decreased from baseline by :
41.9% in the 20mg CBD group
37.2% in the 10mg CBD group
17.2% in the placebo group
Finally, researchers in a study of 120 children and young adults with Dravet syndrome and drug-resistant seizures split participants up into groups taking either 20mg of CBD per kilogram of body weight per day or a placebo.
Results after 14 weeks revealed :
Caregivers also reported a 62% improvement in patients in the cannabidiol group whereas only 34% of the placebo group caregivers could say the same.
Though mild side effects were reported by patients in all studies, it wasn’t enough to deter a majority from continuing the CBD trial.
The most frequently reported side effects of using CBD oil for epilepsy are drowsiness, loss of appetite, insomnia, and diarrhea.
But patients in trials of Epidiolex most often stopped taking CBD due to changes in their liver function.
CBD is processed in the liver, but it may also prevent the breakdown of other drugs, or increase the concentration of them throughout the body. This means those taking antiepileptic drugs may have more of them in their system with the addition of CBD oil.
Patients on valproic acid (VPA), a commonly used anti-seizure medication, did not have increased levels of the drug though some reported liver enzymes that were three times higher than normal with the addition of CBD oil.
Those on clobazam (Onfi) noticed an interaction which made them more tired after taking CBD oil as well.
With careful monitoring and few severe side effects, the reported risks of using CBD oil are relatively low for the potential benefits.
However, it should be noted that CBD dosing recommendations still have have a long road, specifically as it concerns research and the amounts for the everyday user or those with a serious ailment.
Primary factors influencing CBD oil dosage are:
Severity of symptoms
Tolerance of CBD oil
Sex. Due to the presence of additional body fat, females may require lower dosage than males.
Potential drug interactions
Route of administration. Absorption rates of CBD oil from highest to lowest go: Intravenous > Intramuscular > Subcutaneous > Oral.
Time and frequency of dosing
Though over half the states in the US have now legalized medical marijuana, cannabis-derived CBD oil (considered to be a form of medical marijuana), in legal states, is only available through a medical marijuana doctor.
The good news is you can buy full-spectrum CBD oil made from hemp, which comes from the same cannabis plant species as marijuana, without visiting a medical marijuana clinic.Since hemp and hemp-derived products are legal in all 50 states, you can buy hemp CBD oil online and in many health food stores across the country.
FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611046.htm
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. https://www.ncbi.nlm.nih.gov/pubmed/24854329
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481531/
Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome. https://www.nejm.org/doi/10.1056/NEJMoa1714631
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. https://www.ncbi.nlm.nih.gov/pubmed/26724101
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. https://www.nejm.org/doi/full/10.1056/NEJMoa1611618
Cannabidiol: Promise and Pitfalls. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189631/
An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569602/